---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Natural history, survival, and mortality"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Natural history, survival, and mortality. Topics: Age at symptom onset; Long-term course: onset age, symptom-free years, and severity by sex; Course of an attack and attack frequency without treatment; Mortality from laryngeal attacks: German cohort of 728 patients; 8 further topics. 12 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description/natural-history-survival-and-mortality"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Natural history, survival, and mortality

<a id="heading-2.2.1.3"></a>

## 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

### Age at symptom onset

> “Symptoms of hereditary angioedema typically begin in childhood and worsen during puberty.”

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)

<a id="topic-2.2.1.3-2"></a>

### Long-term course: onset age, symptom-free years, and severity by sex

> “Clinical symptoms started at a mean age of 11.2 (SD 7.7) years.”
> “During the following cumulative 5736 years, only 370 (6.5%) symptom-free years occurred.”
> “On average, women had a more severe course of the disease than men.”
> “Patients with early onset of clinical symptoms were affected more severely than those with late onset.”

Source: [Bork et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16490473/)

<a id="topic-2.2.1.3-3"></a>

### Course of an attack and attack frequency without treatment

> “The episodes typically involve nonpruritic, nonpitting swelling that worsens over the first 24 hours and gradually subsides over the next 48 to 72 hours, usually lasting no more than 5–7 days.”
> “Untreated patients with HAE may experience attacks every 7–14 days on average, although some report attacks as frequently as every 3 days, while others may experience them rarely or never.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.3-4"></a>

### Mortality from laryngeal attacks: German cohort of 728 patients

> “Of the 214 patients who had died, 70 asphyxiated during a laryngeal attack.”
> “Mortality by asphyxiation was higher in patients with undiagnosed HAE-C1-INH (63 cases) than in patients with diagnosed HAE-C1-INH (7 cases).”

Source: [Bork et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22841766/)

<a id="topic-2.2.1.3-5"></a>

### Mortality from laryngeal attacks: Brazilian reference-center cohort of 433 patients

> “A total of 75 fatal events were evaluated.”
> “Only 10 of 75 patients were given the diagnosis of HAE before death, and the HAE diagnosis was made after death in 65 of 75 patients using verbal autopsy.”
> “The final cause of death after the investigation was asphyxiation owing to LE in 39 of 75 (52%) and deaths owing to other causes in 36 of 75 (48%).”
> “The life span of patients who died of LE was reduced by 20 years compared with those who died of other causes.”

Source: [Minafra et al. (2022b)](https://pubmed.ncbi.nlm.nih.gov/35526778/)

<a id="topic-2.2.1.3-6"></a>

### Mortality from laryngeal edema: review of 23 real-world studies

> “The analyzed studies included 3292 patients and 411 deaths from asphyxia due to laryngeal edema.”
> “Death rates from laryngeal edema had an average of one death for every 20 patients.”
> “The percentage among deaths in general associated with laryngeal edema was evaluated in three studies (32.7%, 44.4%, and 56%).”

Source: [Minafra et al. (2022a)](https://pubmed.ncbi.nlm.nih.gov/34687444/)

<a id="topic-2.2.1.3-7"></a>

### United States death certificates, 1979 to 2010

> “The age-adjusted death rate for hereditary angioedema decreased from 0.28 (95% confidence interval [CI] 0.25-0.32) to 0.06 (95% CI 0.05-0.08) per million persons per year.”
> “Lack of specific coding for acquired angioedema most likely explains the observed association between cancer and hereditary angioedema.”

Source: [Kim et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25280464/)

<a id="topic-2.2.1.3-8"></a>

### Family deaths from HAE attacks: US patient registry

> “Morbidity surrogates including emergency department visits, hospitalizations, unnecessary abdominal surgeries, and intubations were strikingly high as was mortality with 36.9% of HAE-C1INH and 15.4% of HAE-nl-C1INH participants reporting family members who died from a HAE attack.”

Source: [Christiansen et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37619776/)

<a id="topic-2.2.1.3-9"></a>

### All-cause mortality: Swedish population-based cohort

> “In the current study, there was no increased risk of death (OR 0.69; 95% CI 0.38–1.26) among HAE patients.”
> “Nonetheless, the mortality among HAE patients during the last decade seems to be low.”

Source: [Sundler Björkman et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8967273/)

<a id="topic-2.2.1.3-10"></a>

### Rising prevalence attributed to decreased mortality: Finnish national register

> “The rise in yearly prevalence is likely a combination of stable incidence and decreased mortality, e.g. due to more effective HAE treatment options”

Source: [Sandberg et al. (2024)](https://medicaljournalssweden.se/actadv/article/download/24176/46018/110086)

<a id="topic-2.2.1.3-11"></a>

### Factors associated with in-hospital mortality: US Nationwide Inpatient Sample, 2021

> “Older HA patients and those with autoimmune conditions, hypertension, or low income were at higher risk of mortality.”

Source: [Khalid and Hitch (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12276015/)

<a id="topic-2.2.1.3-12"></a>

### Risk of death from laryngeal edema without a diagnosis

> “In the absence of the HAE diagnosis, the risk of death with laryngeal edema is estimated at 20%–25%.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
